{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:57Z","timestamp":1792813437672,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["Internal grant No. 6028"],"award-info":[{"award-number":["Internal grant No. 6028"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Program Cooperatio"],"award-info":[{"award-number":["Program Cooperatio"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["research area SURG"],"award-info":[{"award-number":["research area SURG"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charles University","id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemo-immunotherapy has transformed the treatment landscape for resectable non-small-cell lung cancer (NSCLC). However, real-world surgical data from nationwide European cohorts remain limited. This study evaluated surgical outcomes and practice patterns during the first year of nationwide implementation of neoadjuvant chemo-immunotherapy with nivolumab in the Czech Republic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter, observational cohort study included all consecutive patients with resectable programmed cell death ligand-1(PD-L1) \u2265\u00a01% NSCLC treated according to the CheckMate 816 protocol (platinum-based chemotherapy plus nivolumab) at all eight accredited thoracic oncology centers in the Czech Republic between August 2023 and August 2024. Surgical and pathological outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-four patients initiated neoadjuvant therapy and 56 (87.5%) underwent resection. Minimally invasive surgery was attempted in 46.4% of cases, with an 11.5% conversion rate. Clavien\u2013Dindo grade \u2265\u00a0III complications occurred in 14.3%, with grade IIIb representing the highest severity. 30-day mortality was 0%. Although 90-day mortality was 5.4%, none of the deaths were directly attributable to surgery. R0 resection was achieved in 98.2%. In the intention-to-treat population, pathological complete response and major pathological response rates were 40.6% and 48.4%, respectively. Pathological complete response was significantly higher in squamous than in non-squamous NSCLC (66.7% vs. 27.6%;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this first nationwide cohort from a European country, early adoption of neoadjuvant chemo-immunotherapy with nivolumab in patients with resectable PD-L1\u00a0\u2265\u00a01% NSCLC was associated with acceptable perioperative outcomes, high R0 resection rates, and substantial pathological response. These results demonstrate the successful adoption of a novel NSCLC treatment modality across a nationwide healthcare system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20310-2","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:13:00Z","timestamp":1785420780000},"page":"10312-10325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-4242","authenticated-orcid":false,"given":"Jiri","family":"Vachtenheim Jr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Casas-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Novysedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Tavandzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Capkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Vajter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Szkorupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Kultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Taskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Koziar Vasakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Skala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Svaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilem","family":"Maly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Hrnciarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Mitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Tulinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslava","family":"Cernekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Ozaniak Strizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matyas","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Palich Fucikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"20310_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12916-024-03844-8","volume":"23","author":"JR Burt","year":"2025","unstructured":"Burt JR, Qaqish N, Stoddard G, Jridi A, Anderson PS, Woods L, et al. Non-small cell lung cancer in ever-smokers vs never-smokers. BMC Med. 2025;23(1):3. https:\/\/doi.org\/10.1186\/s12916-024-03844-8.","journal-title":"BMC Med."},{"issue":"11","key":"20310_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","volume":"36","author":"A Zer","year":"2025","unstructured":"Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1245\u201362. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.003.","journal-title":"Ann Oncol."},{"issue":"12","key":"20310_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.arbres.2022.04.004","volume":"58","author":"D Isla","year":"2022","unstructured":"Isla D, Majem M. A paradigm shift for resectable non-small cell lung cancer. Arch Bronconeumol. 2022;58(12):792\u20133. https:\/\/doi.org\/10.1016\/j.arbres.2022.04.004.","journal-title":"Arch Bronconeumol."},{"issue":"5","key":"20310_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","volume":"165","author":"R Rajaram","year":"2024","unstructured":"Rajaram R, Huang Q, Li RZ, Chandran U, Zhang Y, Amos TB, et al. Recurrence-free survival in patients with surgically resected non-small cell lung cancer: a systematic literature review and meta-analysis. Chest. 2024;165(5):1260\u201370. https:\/\/doi.org\/10.1016\/j.chest.2023.11.042.","journal-title":"Chest."},{"issue":"3","key":"20310_CR5","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.3390\/curroncol30030239","volume":"30","author":"F Petrella","year":"2023","unstructured":"Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, et al. Stage III non-small-cell lung cancer: an overview of treatment options. Curr Oncol. 2023;30(3):3160\u201375. https:\/\/doi.org\/10.3390\/curroncol30030239.","journal-title":"Curr Oncol."},{"issue":"21","key":"20310_CR6","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.13.9030.","journal-title":"J Clin Oncol."},{"key":"20310_CR7","doi-asserted-by":"publisher","first-page":"1286104","DOI":"10.3389\/fonc.2023.1286104","volume":"13","author":"S Kalvapudi","year":"2023","unstructured":"Kalvapudi S, Vedire Y, Yendamuri S, Barbi J. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges. Front Oncol. 2023;13:1286104. https:\/\/doi.org\/10.3389\/fonc.2023.1286104.","journal-title":"Front Oncol."},{"issue":"21","key":"20310_CR8","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med."},{"issue":"6","key":"20310_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983.","journal-title":"N Engl J Med."},{"issue":"18","key":"20310_CR10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med."},{"issue":"19","key":"20310_CR11","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","journal-title":"N Engl J Med."},{"issue":"8","key":"20310_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393(8):741\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","journal-title":"N Engl J Med."},{"issue":"1","key":"20310_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thorsurg.2025.09.008","volume":"36","author":"G Yavuz","year":"2026","unstructured":"Yavuz G, Spicer JD. Neoadjuvant chemoimmunotherapy. Thorac Surg Clin. 2026;36(1):9\u201323. https:\/\/doi.org\/10.1016\/j.thorsurg.2025.09.008.","journal-title":"Thorac Surg Clin."},{"issue":"10","key":"20310_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/14712598.2024.2408292","volume":"24","author":"M Sposito","year":"2024","unstructured":"Sposito M, Eccher S, Scaglione I, Avancini A, Rossi A, Pilotto S, et al. The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents. Expert Opin Biol Ther. 2024;24(10):1025\u201337. https:\/\/doi.org\/10.1080\/14712598.2024.2408292.","journal-title":"Expert Opin Biol Ther."},{"key":"20310_CR15","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.lanepe.2024.100840","volume":"38","author":"I Houda","year":"2024","unstructured":"Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, Provencio M, Levy A, et al. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. Lancet Reg Health Eur. 2024;38:100840. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100840.","journal-title":"Lancet Reg Health Eur."},{"key":"20310_CR16","doi-asserted-by":"publisher","first-page":"1436077","DOI":"10.3389\/fonc.2024.1436077","volume":"14","author":"V Gristina","year":"2024","unstructured":"Gristina V, Eze C. Editorial: real-world data and real-world evidence in lung cancer. Front Oncol. 2024;14:1436077. https:\/\/doi.org\/10.3389\/fonc.2024.1436077.","journal-title":"Front Oncol."},{"issue":"18","key":"20310_CR17","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1002\/cncr.70081","volume":"131","author":"AJ Cooper","year":"2025","unstructured":"Cooper AJ, Garbo E, Arfe A, Conroy M, Shaverdian N, Bott M, et al. Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival. Cancer. 2025;131(18):e70081. https:\/\/doi.org\/10.1002\/cncr.70081.","journal-title":"Cancer."},{"issue":"3","key":"20310_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cllc.2024.12.010","volume":"26","author":"A Brunelli","year":"2025","unstructured":"Brunelli A, Hoffman R, Wotton R, Baijal S, Bhatnagar P, Clarke K, et al. Surgical and pathological results following neoadjuvant nivolumab and platinum-based chemotherapy for locally advanced resectable NSCLC: a multicentre real-world series from England. Clin Lung Cancer. 2025;26(3):253\u201361. https:\/\/doi.org\/10.1016\/j.cllc.2024.12.010.","journal-title":"Clin Lung Cancer."},{"issue":"10","key":"20310_CR19","doi-asserted-by":"publisher","first-page":"ezaf343","DOI":"10.1093\/ejcts\/ezaf343","volume":"67","author":"A Brunelli","year":"2025","unstructured":"Brunelli A, Mariolo A, Aigner C, De Antonio DG, Jimenez M, Hemead H, et al. Surgical results after neoadjuvant nivolumab and platinum-based chemotherapy for resectable lung cancer. A multicentre European real clinical practice analysis. Eur J Cardiothorac Surg. 2025;67(10):ezaf343. https:\/\/doi.org\/10.1093\/ejcts\/ezaf343.","journal-title":"Eur J Cardiothorac Surg."},{"key":"20310_CR20","doi-asserted-by":"publisher","first-page":"100841","DOI":"10.1016\/j.lanepe.2024.100841","volume":"38","author":"I Houda","year":"2024","unstructured":"Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, Provencio M, et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician\u2019s perspective. Lancet Reg Health Eur. 2024;38:100841. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100841.","journal-title":"Lancet Reg Health Eur."},{"issue":"10","key":"20310_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","volume":"19","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer. J Thorac Oncol. 2024;19(10):1373\u2013414. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.010.","journal-title":"J Thorac Oncol."},{"issue":"21","key":"20310_CR22","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.3390\/jcm13216568","volume":"13","author":"W Shalata","year":"2024","unstructured":"Shalata W, Daher S, MaimonRabinovitch N, Shamai S, Kian W, Turgeman I, et al. Real-world clinical outcomes of neoadjuvant platinum-based chemotherapy with nivolumab in non-small cell lung cancer. J Clin Med. 2024;13(21):6568. https:\/\/doi.org\/10.3390\/jcm13216568.","journal-title":"J Clin Med."},{"issue":"6","key":"20310_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.athoracsur.2025.09.051","volume":"121","author":"J Seitlinger","year":"2026","unstructured":"Seitlinger J, Salko O, BulgarelliMaqueda L, Meng A, Tetu M, Desilets A, et al. Neoadjuvant chemotherapy-immunotherapy in non-small cell lung cancer: can positron emission tomography scan predict complete pathologic response? Ann Thorac Surg. 2026;121(6):1347\u201355. https:\/\/doi.org\/10.1016\/j.athoracsur.2025.09.051.","journal-title":"Ann Thorac Surg."},{"issue":"1","key":"20310_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thorsurg.2025.09.007","volume":"36","author":"O Ostrovetsky","year":"2026","unstructured":"Ostrovetsky O, Chudgar NP. Surgical challenges after neoadjuvant therapy. Thorac Surg Clin. 2026;36(1):41\u20138. https:\/\/doi.org\/10.1016\/j.thorsurg.2025.09.007.","journal-title":"Thorac Surg Clin."},{"key":"20310_CR25","doi-asserted-by":"publisher","first-page":"1134713","DOI":"10.3389\/fonc.2023.1134713","volume":"13","author":"J Zeng","year":"2023","unstructured":"Zeng J, Yi B, Chang R, Chen Y, Yu Z, Gao Y. Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Front Oncol. 2023;13:1134713. https:\/\/doi.org\/10.3389\/fonc.2023.1134713.","journal-title":"Front Oncol."},{"issue":"3","key":"20310_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Neotorch I, et al. Perioperative Toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024;331(3):201\u201311. https:\/\/doi.org\/10.1001\/jama.2023.24735.","journal-title":"JAMA."},{"issue":"2","key":"20310_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13(2):119\u201329. https:\/\/doi.org\/10.1016\/S2213-2600(24)00269-8.","journal-title":"Lancet Respir Med."},{"key":"20310_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.xjon.2022.09.012","volume":"12","author":"HA Feldman","year":"2022","unstructured":"Feldman HA, Zhou N, Deboever N, Hofstetter W, Mehran R, Rajaram R, et al. Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity. JTCVS Open. 2022;12:372\u201384. https:\/\/doi.org\/10.1016\/j.xjon.2022.09.012.","journal-title":"JTCVS Open."},{"issue":"10","key":"20310_CR29","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.jtocrr.2021.100221","volume":"2","author":"JM Lee","year":"2021","unstructured":"Lee JM, Kim AW, Marjanski T, Falcoz PE, Tsuboi M, Wu YL, et al. Important surgical and clinical end points in neoadjuvant immunotherapy trials in resectable NSCLC. JTO Clin Res Rep. 2021;2(10):100221. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100221.","journal-title":"JTO Clin Res Rep."},{"issue":"3","key":"20310_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jtcvs.2022.10.007","volume":"165","author":"VW Rusch","year":"2023","unstructured":"Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, et al. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023;165(3):828\u201339. https:\/\/doi.org\/10.1016\/j.jtcvs.2022.10.007.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"25","key":"20310_CR31","doi-asserted-by":"publisher","first-page":"00347","DOI":"10.1016\/j.arbres.2025.09.015","volume":"S0300\u20132896","author":"M Provencio","year":"2025","unstructured":"Provencio M, Counago F. Immunotherapy in Early-stage non-small cell lung cancer: A PRO\/CON debate. Arch Bronconeumol. 2025;S0300\u20132896(25):00347\u201353. https:\/\/doi.org\/10.1016\/j.arbres.2025.09.015.","journal-title":"Arch Bronconeumol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20310-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20310-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20310-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:22:53Z","timestamp":1792207373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20310-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20310"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20310-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Vachtenheim Jr has received consultancy fees for speaker honoraria from Bristol Myers Squibb and travel reimbursements from AstraZeneca. Dr. Casas-Mendez has received speaker honoraria and travel grants and has served on advisory boards for Bristol Myers Squibb. Dr. Capkova has received honoraria for lectures from AstraZeneca, Merck, MSD, BMS, and Roche and has served on the advisory board for Merck and BMS. Dr. Szkorupa has received consultancy fees for speaker honoraria from Bristol Myers Squibb. Dr. Kultan has received consultancy fees for speaker honoraria from\u00a0Janssen, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Ewopharma, Pfizer, Amgen, Angelini, Gedeon Richter, GlaxoSmithKline, Johnson & Johnson, and Roche. Dr. Svaton has received financial income (lecturing and advisory boards) and educational support from Astra Zeneca, BMS, MSD, and Roche. Dr. Sulc has received honoraria and consulting fees from Pierre Fabre, BMS, and MSD. Dr. Hrnciarik has received consultancy fees for advisory board roles with AstraZeneca, BMS, and Roche. Dr. Bratova has received consultancy fees from BMS, AstraZeneca, MSD, Johnson & Johnson, and Pfizer.\u00a0Dr. Cernekova has received consultancy fees for an advisory board role from BMS. Dr. Kuhn worked as a statistician for clinical trials and research projects sponsored by pharmaceutical companies such as AstraZeneca, Novartis, and AOP health. Dr. Sepesi has received consultancy fees for speaker honoraria from AstraZeneca. Dr. Lischke has received consultancy fees for work as an advisor and speaker for AstraZeneca, MSD, BMS, and proctor for Intuitive Surgical. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors acknowledge the use of ChatGPT (OpenAI, version February 2026) for grammatical corrections and phrasing refinements in the preparation of this manuscript. All content was thoroughly reviewed and approved by the investigators to ensure accuracy, scientific rigor, and adherence to ethical standards. The use of AI-assisted tools was limited to language enhancement and did not influence the study design, data analysis, or conclusions.","order":2,"name":"Ethics","label":"Use of AI","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}